1X10^6 PHA treated (3d) human PBMCs were surface stained with 0.2 ug Anti-Human PD-L1 (B7-H1) (65081-1-Ig, Clone:29E.2A3) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (red), or Mouse IgG2b Isotype Control (blue). 1X10^6 untreated human PBMCs were surface stained with 0.2 ug Anti-Human PD-L1 (B7-H1) (65081-1-Ig, Clone:29E.2A3) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (black dashed). Cells were not fixed. Lymphocytes were gated.
1X10^6 PHA treated (3d) human PBMCs were surface stained with 0.2 ug Anti-Human PD-L1 (B7-H1) (65081-1-Ig, Clone:29E.2A3) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (right), or Mouse IgG2b Isotype Control (left). 1X10^6 untreated human PBMCs were surface stained with 0.2 ug Anti-Human PD-L1 (B7-H1) (65081-1-Ig, Clone:29E.2A3) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (center). Cells were not fixed. Lymphocytes were gated.
